Evidence map›Paper›PMID 36400304›Full record

ArticleInternational journal of radiation oncology, biology, physics2023

Prevention of Radiation-Induced Bladder Injury: A Murine Study Using Captopril.

Angela M Groves, Nicole Paris, Eric Hernady, Carl J Johnston, Omar Aljitawi, Yi-Fen Lee, Sarah L Kerns, Brian Marples

Open access · hybridAbstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Modeling normal bladder injury after radiation therapy.International journal of radiation biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Angela M GrovesDepartments of Radiation Oncology, University of Rochester, Rochester, New York.
Nicole ParisDepartments of Radiation Oncology, University of Rochester, Rochester, New York.
Eric HernadyDepartments of Radiation Oncology, University of Rochester, Rochester, New York.
Carl J JohnstonDepartments of Pediatrics, University of Rochester, Rochester, New York.
Omar AljitawiDepartments of Medicine, Hematology/Oncology, University of Rochester, Rochester, New York.
Yi-Fen LeeDepartments of Urology, University of Rochester, Rochester, New York.
Sarah L KernsDepartments of Radiation Oncology, University of Rochester, Rochester, New York.
Brian MarplesDepartments of Radiation Oncology, University of Rochester, Rochester, New York. Electronic address: Brian_Marples@URMC.Rochester.edu.
University of Rochester · US

Funding

Targeting angiotensin and inflammation to prevent radiotherapy-induced bladder toxicity.R01CA291956 · NCI · UNIVERSITY OF ROCHESTER · PI Sarah L. Kerns, BRIAN MARPLES · 2024 to 2026
$2.7M
SARRP 200 Platform for Image Guided Micro IrradiationS10OD021548 · OD · UNIVERSITY OF ROCHESTER · PI WILLIAMS, JACQUELINE PATRICIA · 2016 to 2016
$600k
NCI NIH HHS R01 CA291956NIH HHS S10 OD021548
6 · The paper itself

Abstract

purposePelvic radiation therapy (RT) can cause debilitating bladder toxicities but few clinical interventions exist to prevent injury or alleviate symptoms. From a large genome-wide association study in patients with prostate cancer it was previously reported that SNPs tagging AGT, part of the renin-angiotensin system (RAS), correlated with patient-reported late hematuria, identifying a potential targetable pathway to prevent RT-induced bladder injury. To investigate this association, we performed a preclinical study to determine whether RAS modulation protected the bladder against RT injury. METHODS AND MATERIALS: C57BL/6 male mice were treated with an oral angiotensin converting enzyme inhibitor (ACEi: 0.3g/L captopril) 5 days before focal bladder X-irradiation with either single dose (SD) 30 Gy or 3 fractions of 8 Gy (8 Gy × 3 in 5 days). RT was delivered using XStrahl SARRP Muriplan CT-image guidance with parallel-opposed lateral beams. ACEi was maintained for 20 weeks post RT. Bladder toxicity was assessed using assays to identify local injury that included urinalysis, functional micturition, bladder-released exosomes, and histopathology, as well as an assessment of systemic changes in inflammatory-mediated circulating immune cells.

resultsSD and fractionated RT increased urinary frequency and reduced the volume of individual voids at >14 weeks, but not at 4 weeks, compared with nonirradiated animals. Urothelial layer width was positively correlated with mean volume of individual voids (P = .0428) and negatively correlated with number of voids (P = .028), relating urothelial thinning to changes in RT-mediated bladder dysfunction. These chronic RT-induced changes in micturition patterns were prevented by captopril treatment. Focal bladder irradiation significantly increased the mean particle count of urine extracellular vesicles and the monocyte and neutrophil chemokines CCL2 and MIP-2, and the proportions of circulating inflammatory-mediated neutrophils and monocytes, which was also prevented by captopril. Exploratory transcriptomic analysis of bladder tissue implicated inflammatory and erythropoietic pathways.

conclusionsThis study demonstrated that systemic modulation of the RAS protected against and alleviated RT-induced late bladder injury but larger confirmatory studies are needed.

Indexed as

CaptoprilRadiation InjuriesAngiotensin-Converting Enzyme InhibitorsAnimalsGenome-Wide Association StudyMaleMiceMice, Inbred C57BLUrinary BladderAngiotensin-Converting Enzyme InhibitorsCaptopril

Identifiers

PMID36400304
PMCPMC12210348
OpenAlexW4309335283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.